MX2016015791A - Composiciones de omega-3, formas de dosis, y metodos de uso. - Google Patents

Composiciones de omega-3, formas de dosis, y metodos de uso.

Info

Publication number
MX2016015791A
MX2016015791A MX2016015791A MX2016015791A MX2016015791A MX 2016015791 A MX2016015791 A MX 2016015791A MX 2016015791 A MX2016015791 A MX 2016015791A MX 2016015791 A MX2016015791 A MX 2016015791A MX 2016015791 A MX2016015791 A MX 2016015791A
Authority
MX
Mexico
Prior art keywords
compositions
dosage forms
omega
methods
disclosed
Prior art date
Application number
MX2016015791A
Other languages
English (en)
Spanish (es)
Inventor
Sandnes Olav
A Miller Bruce
Dyerberg Jorn
Stender Steen
Original Assignee
Marine Ingredients Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Marine Ingredients Llc filed Critical Marine Ingredients Llc
Publication of MX2016015791A publication Critical patent/MX2016015791A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/60—Fish, e.g. seahorses; Fish eggs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
MX2016015791A 2014-06-06 2015-06-05 Composiciones de omega-3, formas de dosis, y metodos de uso. MX2016015791A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462009145P 2014-06-06 2014-06-06
US201462019289P 2014-06-30 2014-06-30
PCT/US2015/034372 WO2015188046A1 (en) 2014-06-06 2015-06-05 Omega-3 compositions, dosage forms, and methods of use

Publications (1)

Publication Number Publication Date
MX2016015791A true MX2016015791A (es) 2017-05-30

Family

ID=54767418

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016015791A MX2016015791A (es) 2014-06-06 2015-06-05 Composiciones de omega-3, formas de dosis, y metodos de uso.

Country Status (14)

Country Link
US (4) US9675575B2 (enExample)
EP (2) EP3906920A1 (enExample)
JP (2) JP6755186B2 (enExample)
KR (1) KR102400958B1 (enExample)
CN (1) CN106687113B (enExample)
AU (1) AU2015269307C1 (enExample)
BR (1) BR112016028561A8 (enExample)
CA (1) CA2950344C (enExample)
CL (1) CL2016003131A1 (enExample)
MX (1) MX2016015791A (enExample)
MY (1) MY186566A (enExample)
RU (1) RU2741965C2 (enExample)
TW (1) TWI725937B (enExample)
WO (1) WO2015188046A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10709680B2 (en) * 2011-07-18 2020-07-14 Physicians Recommended Nutriceuticals, Llc Methods for treating dry eye
CN106687113B (zh) * 2014-06-06 2021-09-03 海洋原料公司 ω-3组合物、剂型及使用方法
CN110958731A (zh) 2018-09-21 2020-04-03 鸿盛国际有限公司 发光二极管并联电路
FR3103355B1 (fr) 2019-11-26 2024-05-31 Polaris Composition d’huile de micro-organismes enrichie en acides gras polyinsaturés
FR3151183A1 (fr) 2023-07-20 2025-01-24 Microphyt Nouvelle utilisation d’un extrait de la microalgue Phaeodactylum tricornutum

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8819110D0 (en) 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
FR2731015B1 (fr) 1995-02-24 1997-05-30 Sci Sartone Procede d'enrichissement enzymatique d'huiles d'origine marine et les triglycerides d'acides gras polyinsatures ainsi obtenus
JP2000501131A (ja) * 1995-11-24 2000-02-02 ロダース・クロックラーン・ビー・ブイ 魚油をベースとする組成物
US7799365B2 (en) * 2001-04-06 2010-09-21 Burnbrae Farms Limited Liquid egg composition including fish oil with omega-3 fatty acid
US7169385B2 (en) 2003-09-29 2007-01-30 Ronald G. Udell Solubilized CoQ-10 and carnitine
SE0303513D0 (sv) 2003-12-19 2003-12-19 Pronova Biocare As Use of a fatty acid composition comprising at least one of epa and dha or any combinations thereof
US20070020340A1 (en) * 2005-07-25 2007-01-25 David Rubin Fish oil products for reducing cholesterol, low density lipoprotein, and hypertension
US20090182050A1 (en) 2005-10-07 2009-07-16 Ocean Nutrition Canada, Ltd. Salts of Fatty Acids and Methods of Making and Using thereof
CA2634139C (en) 2005-12-20 2015-06-23 Cenestra, Llc. Omega 3 fatty acid formulations
US9265745B2 (en) 2005-12-21 2016-02-23 Brudy Technology S.L. Use of DHA, EPA or DHA-derived EPA for treating a pathology associated with cellular oxidative damage
CA2655769A1 (en) 2006-06-23 2007-12-27 The Procter & Gamble Company Concentrated omega-3 fatty acids and mixtures containing them
WO2008036353A2 (en) 2006-09-19 2008-03-27 The Trustees Of Columbia University In The City Of New York Omega-3 diglyceride emulsions
EP2147088A4 (en) * 2007-04-26 2010-05-05 Patrick Adlercreutz FERTILIZED MILK OILS COMPRISING MULTIPLE-UNSATURATED FATTY ACIDS, COMPRISING EICOSAPENTAIC ACID (EPA) AND DOCOSAHEXAIC ACID (DHA), AND MANUFACTURING METHOD THEREFOR
US20100119600A1 (en) 2007-06-01 2010-05-13 Joar Opheim Substances for reducing occurrence of major cardiac events comprising red yeast rice extract and omega-3 polyunsaturated fatty acid or derivative thereof
CL2008002020A1 (es) 2007-07-12 2008-11-14 Ocean Nutrition Canada Ltd Metodo de modificacion de un aceite, que comprende hidrolizar gliceridos con una solucion de lipasa thermomyces lanuginosus, separar la fraccion de acido graso saturado de la fraccion de glicerido hidrolizado y esterificar los gliceridos hidrolizados en la presencia de candida antarctica lipasa b; y composicion de aceite.
WO2009017102A1 (ja) * 2007-07-30 2009-02-05 Nippon Suisan Kaisha, Ltd. Epa濃縮油およびdha濃縮油の製造方法
KR101045397B1 (ko) 2008-07-04 2011-06-30 주식회사동우산업 오메가-3 지방산 함량이 높은 정제 오징어유의 제조방법
GB0813599D0 (en) 2008-07-24 2008-09-03 Pharma Marine As Method
RS53694B1 (sr) * 2008-08-07 2015-04-30 Spa Societa' Prodotti Antibiotici S.P.A. Dugoročno lečenje simptomatske srčane insuficijencije
US20100236137A1 (en) * 2008-09-23 2010-09-23 LiveFuels, Inc. Systems and methods for producing eicosapentaenoic acid and docosahexaenoic acid from algae
AU2010222648B2 (en) * 2009-03-09 2016-07-07 Pronova Biopharma Norge As Compositions comprising a fatty acid oil mixture and a surfactant, and methods and uses thereof
CN101695487B (zh) * 2009-09-22 2012-01-18 北京百慧生化制药有限责任公司 一种高纯度epa-e、dha-e的多烯酸乙酯乳剂
FR2955459B1 (fr) 2010-01-28 2013-11-22 Polaris Composition huileuse riche en monoglycerides de dha
US20110223246A1 (en) * 2010-03-10 2011-09-15 Joar Opheim Docosahexaenoic acid bound in phospholipids and method of recovering same from a natural source
WO2011133841A2 (en) 2010-04-23 2011-10-27 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Intravenous omega-3 fatty acid compositions & method of use
KR101904392B1 (ko) * 2010-09-24 2018-10-05 프로노바 바이오파마 너지 에이에스 오메가-3 지방산을 농축하기 위한 공정
US20120252888A1 (en) * 2011-03-29 2012-10-04 Palupa Medical Ltd. Compositions and Methods for Treating Neurologic Disorders
AU2012347606A1 (en) * 2011-12-08 2014-06-26 Metaproteomics, Llc Supplemented oil compositions and methods for improved health
WO2013093630A2 (en) * 2011-12-22 2013-06-27 Pronova Biopharma Norge As Gelatin/alginate delayed release capsules comprising omega-3 fatty acids, and methods and uses thereof
CN110478342A (zh) 2012-05-10 2019-11-22 索卢泰克斯Na有限责任公司 含有天然专门促消退介质及其前体的具有抗炎活性的油
EP3756658A1 (en) 2012-09-24 2020-12-30 Aker Biomarine Antarctic As Omega -3 compositions
US20130310457A1 (en) 2013-07-25 2013-11-21 Niral Ramesh Solid-in-oil dispersions
CN106687113B (zh) * 2014-06-06 2021-09-03 海洋原料公司 ω-3组合物、剂型及使用方法

Also Published As

Publication number Publication date
AU2015269307A1 (en) 2017-01-05
RU2016149416A (ru) 2018-07-10
BR112016028561A2 (pt) 2017-08-22
RU2741965C2 (ru) 2021-02-01
US20210308086A1 (en) 2021-10-07
AU2015269307C1 (en) 2019-10-03
RU2016149416A3 (enExample) 2018-12-05
US20160243068A1 (en) 2016-08-25
KR20170018825A (ko) 2017-02-20
US9675575B2 (en) 2017-06-13
CA2950344A1 (en) 2015-12-10
US20180303784A1 (en) 2018-10-25
WO2015188046A1 (en) 2015-12-10
AU2015269307B2 (en) 2019-03-14
TW201613571A (en) 2016-04-16
EP3151826A4 (en) 2018-01-24
US11160777B2 (en) 2021-11-02
JP6755186B2 (ja) 2020-09-16
CN106687113A (zh) 2017-05-17
CA2950344C (en) 2023-09-19
EP3151826A1 (en) 2017-04-12
EP3906920A1 (en) 2021-11-10
US20170252313A1 (en) 2017-09-07
MY186566A (en) 2021-07-27
US10172819B2 (en) 2019-01-08
BR112016028561A8 (pt) 2021-06-29
TWI725937B (zh) 2021-05-01
US10034849B2 (en) 2018-07-31
JP2020105224A (ja) 2020-07-09
KR102400958B1 (ko) 2022-05-20
CL2016003131A1 (es) 2017-06-09
CN106687113B (zh) 2021-09-03
JP2017516811A (ja) 2017-06-22

Similar Documents

Publication Publication Date Title
IL268406A (en) Preparations and methods for treating hemoglobin diseases
IL260257A (en) Preparations and methods for the treatment of hemoglobinopathies
EP4620520A3 (en) Methods and compositions relating to chondrisomes
DK3889145T3 (da) 8-cyano-5-piperidino-quinoliner som TLR7/8-antagonister og anvendelser deraf til behandling af immunsygdomme
IL290150A (en) Compounds and methods for treating chronic pain
GB2541571A (en) Pharmaceutical compositions
IL262348A (en) Preparations for the treatment of excessive radiation disorders
MX2017002489A (es) Agentes terapeuticos humanos.
MY190647A (en) Compounds effective in treating hepatotoxicity and fatty liver diseases and uses thereof
IL246856A0 (en) A combination of baclofen, acamprosate and medium chain triglycerides for the treatment of neurological disorders
PH12016502530A1 (en) Pharmaceutical compositions comprising dgla and use of same
TW201613571A (en) OMWGA-3 compositions, dosage forms, and methods of use
LT3229790T (lt) Kompozicijos, apimančios vidutinės grandinės trigliceridus, skirtos panaudoti epilepsijos gydyme
ZA201807858B (en) Plant treatment composition
AP2017009707A0 (en) Coix seed oil comprising 11 triglycerides, formulation and application thereof
EP3169684A4 (en) Methods and compositions for treating hiv-related disorders
GEP20196977B (en) Pharmaceutical formulations of vildagliptin
PH12016502311A1 (en) Omega-3 analogues
EP3673073A4 (en) PRODUCTION OF EPA- AND DHA-ENRICHED GLYCERIDES
GEP201706795B (en) Hexahydrofuropyrroles as pde1 inhibitors
WO2015191760A3 (en) Compositions and methods for treating rheumatoid arthritis
HUE039425T2 (hu) 3,4-Diamino-6-klórpirazin-2-karboxamid vegyületek enac által mediált betegségek kezelésére
WO2015123480A3 (en) Compositions and methods for the prevention and/or treatment of schistosomiasis
HK40015941A (en) Compositions and methods for the treatment of hemoglobinopathies
HK1228312A1 (en) Methods of treating celiac disease with larazotide